Annovis Bio (Annovis Bio) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Change In Receivables?

Annovis Bio's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Annovis Bio's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Annovis Bio's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Annovis Bio's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Annovis Bio's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Annovis Bio's liquidation value for the three months ended in Dec. 2023 was $-12.20 Mil.

Annovis Bio Change In Receivables Historical Data

The historical data trend for Annovis Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Change In Receivables Chart

Annovis Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.74

0.74

Annovis Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Annovis Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Annovis Bio (NYSE:ANVS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Annovis Bio's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Annovis Bio's accounts receivable are only considered to be worth 75% of book value:

Annovis Bio's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.755	-	17.959	+	0.75 * 0	+	0.5 * 0
=	-12.20

Annovis Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Annovis Bio (Annovis Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

07X:Germany

Address

1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312

Website

https://www.annovisbio.com

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

Executives

Henry Iii Hagopian	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White	director	227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck	director	4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini	director, officer: President and CEO	1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy	director	1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty	officer: Chief Financial Officer	360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M.	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831